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Background: The study of COMT gene polymorphisms in migraine could be of particular interest since impaired
catecholaminergic neurotransmission, namely chronic dopaminergic and noradrenergic hypofunction, is a peculiar
migraine trait. In this study, for the first time, we focused on the role of COMT rs4818 genetic variant, the
polymorphism most strongly affecting COMT activity, in migraine. This study was conducted in a cohort of carefully
clinical characterized Caucasian migraineurs recruited in a specifically dedicated migraine biobank, providing also a
replication study on rs4680 polymorphism.
Findings: Genotyping of rs4680 and rs4818 Catechol-O-Methyltransferase gene polymorphisms was performed on
380 unrelated migraine patients, and 132 healthy subjects matched for age, gender and race-ethnicity, with no
clinical evidence or family history of migraine or other neurological diseases. The rs4680 and rs4818 genotypic
frequencies did not deviate from those expected for a population in Hardy-Weinberg equilibrium and did not
correlate with demographics or clinical migraine features, even when considering migraine subtypes such as
dopaminergic migraine, menstrual migraine, and menstrually related migraine.
Conclusions: COMT genotype does not influence migraine susceptibility or phenotype, even considering rs4818
polymorphism and peculiar clinical subtypes. This finding prompts to go over COMT to explain catecholamine
derangement in migraine, exploring enzymes involved in catecholamines synthesis and catabolism, such as
monoamine-oxidase, dopamine beta-hydroxylase, tyrosine-hydroxylase or tyrosine-decarboxylase, among others.
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Non-physiological catecholamine levels play a major role
in migraine aetiology [1]. Clinical, pharmacological and
biochemical evidence point to a chronic dopaminergic
and noradrenergic dysfunction in migraine. Of note, some
patients show during the attack symptoms related to
dopamine receptor stimulation such as yawning, somno-
lence and vomiting or to reduced sympathetic function* Correspondence: raffaele.palmirotta@sanraffaele.it
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reproduction in any medium, provided the origsuch hypotension and, occasionally, syncope [2,3]. The
deciphering of the biological basis (biotype) of these
clinical phenotypes would allow a more precise compre-
hension of migraine mechanisms and a more tailored
migraine treatment.
The Catechol-O-Methyltransferase (COMT) gene [OM
IM:+116790], mapping on chromosome 22q11.21, encodes
for the major enzyme that degrades catecholamines (dopa-
mine, epinephrine, and norepinephrine). Two COMT tran-
scripts isoforms are produced, leading to the synthesis of a
soluble protein (S-COMT), localized in blood and periph-
eral tissues, and a membrane-bound protein (MB-COMT)
concentrated in the brain, mainly in the prefrontal cortexs is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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which result in a marked clinical significance. The rs4680
causes a substitution of a Valine (Val: GTG) to Methionine
(Met: ATG) at codon 158 for MB-COMT isoform, and at
codon 108 for S-COMT isoform [4,5]. These functional
amino acid changes lead to a higher dopamine-degrading
activity (H: high) for the Val158 variant and to a lower
thermostability and enzymatic activity (L: lower) for the
Met158 variant [6-8]. COMT activity is 3 to 4 times higher
in Val homozygous compared to Met homozygous geno-
type carriers [9]. The rs4680 has been related to human
pain perception, cognitive phenotypes, psychiatric disor-
ders and variations in brain activation and structure [4,10].
The synonymous polymorphism rs4818 causes a C/G sub-
stitution at codon 86 of S-COMT and 136 of MB-COMT,
corresponding to a Leucine residue. This genetic variant is
related to a haploblock comprising rs6269 (A/G), rs4633
(C/T), rs4818 (G/C) and rs4680 (A/G), which strongly
affects the efficiency of protein synthesis based on the
specific haplotype, leading to a huge variation in enzyme
activity [11]. Three major haplotypes influencing COMT
activity and pain sensitivity were identified: a “low pain
sensitivity” haplotype (G-C-G-G), characterized by a 11.4
times higher COMT activity compared with the “high pain
sensitivity” haplotype (A-C-C-G), and an “average pain
sensitivity” haplotype (A-T-C-A), with intermediate COMT
activity values [11]. Variability at the rs4818 has been cor-
related to cognitive functions: the G allele, corresponding
to high COMT activity levels and low tonic prefrontal cor-
tex dopamine signalling, has been associated to a less effi-
cient planning and problem solving ability, lower prepulse
inhibition levels and working memory performance [12].
The study of COMT polymorphism in migraine has
been mainly focused on the rs4680 polymorphism (Table 1)
however providing inconclusive results, mainly due to
small sampling and poor patients’ clinical characterization
[13-21]. Surprisingly, the rs4818 polymorphism, despite its
strong influence on COMT activity, has still not been
investigated. We also noticed that the combined assess-
ment of rs4680 and rs4818 was sufficient to provide a
high degree of informativeness relatively to the over-
mentioned haplotypes [11].
Therefore, in the present study we sought to study the
relationship between COMT rs4818 polymorphism and
migraine in a detailed clinical migraine Caucasian popula-
tion, whose biological samples were stored in a specifically
dedicated migraine biobank (Interinstitutional Multidiscip-
linary BioBank-BioBIM), providing also a replication study
on rs4680 polymorphism [22].
Findings
Populations
Three hundred-eighty Mediterranean Caucasian unrelated
individuals affected by migraine without aura (MwoA, n =189; M/F = 34/155; mean age 40.3 ± 11.9 yrs), migraine
with aura (MwA, n = 65; M/F = 16/49; mean age 39.4 ±
12.6 yrs) or chronic migraine (CM, n = 126; M/F = 14/112;
mean age 47.5 ± 13.3 yrs) were consecutively recruited at
our Headache and Pain Unit (IRCCS San Raffaele Pisana,
Rome) from 01/01/2012 to 31/12/2013 [23,24].
As controls we enrolled 132 healthy subjects (M/F = 57/
75; mean age 38.3 ± 12.4 yrs) with no clinical evidence or
family history of migraine or other neurological diseases,
matched for age, gender and race-ethnicity. Informative
and consent forms by the institutional Ethics Committee
of San Raffaele Scientific Institute were provided to both
groups, together with the permission to obtain blood sam-
ples for research purposes. The protocol was approved by
the institutional review board at San Raffaele Scientific In-
stitute and have therefore been performed in accordance
with the ethical standards laid down in the 1964 Declar-
ation of Helsinki. All subjects gave their informed consent
prior to their inclusion in the study.
Assessment of migraineurs’ clinical characteristics
All migraineurs underwent a complete physical, neuro-
logical and fundoscopic examination. Detailed information
on patients’ socio-demographic characteristics, lifestyle,
migraine features, concomitant diseases and medications
were gathered with face-to-face interviews using a semi-
structured questionnaire. Migraine features included
disease duration, family history of migraine, migraine
type (episodic, chronic, MwoA, MwA, pure menstrual,
menstrually-related [24]), frequency and duration of at-
tacks, location, quality and intensity of pain, presence of
dopaminergic symptoms (assessed by asking: ”Before or
during the attack do you present yawning, vomiting or
somnolence?), presence of unilateral cranial parasympa-
thetic symptoms, response to triptans (rated as absent/
poor, fair, good/excellent), duration of chronic migraine,
preventive and acute treatment, presence and duration
of medication overuse.
DNA extraction and genotyping
All biological samples were stored at the BioBIM of IRCCS
San Raffaele Pisana following the biobanking Standard
Operative Procedures (SOPs) [25]. DNA was isolated from
ethylenediaminetetraacetate (EDTA) anticoagulated whole
blood using MagNApure LC instrument and the Mag-
NApure LC total DNA isolation kit I (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manu-
facturer’s instructions.
COMT polymorphisms rs4818 and rs4680 were deter-
mined by a 261-bp standard PCR amplification in a Gen-
eAmp PCR System 9700 (Applied Biosystems, Carlsbad,
CA, USA) using HotStarTaq Master Mix (HotStarTaq
Master Mix Kit, QIAGEN, Inc., Chatsworth, CA, USA) on
the basis of the COMT Ensembl sequence [Ensembl:
Table 1 Reported association studies between COMT polymorphisms and migraine (pts: patients)
Patients (M/F) Headache subtype Healthycontrols (M/F) Mean age (years)
Country,
Race-Ethnicity Polymorphism Comment Reference
62 (11/51) -Migraine with aura (33)
64 (14/50)
-Patients (32 ± 5.2)
Turkey, Asian rs4680
Association between the Met
allele and migraine (P = 0.013)
and with family history of
migraine (P = 0.003).
Emin Erdal et al., 2001 [13]






No association with migraine.
Hagen et al., 2006 [14]
Association of the Val/Val
genotype with non-migrainous
headache in female patients
(P = 0.04).
-Non-migrainous headache (677) -Controls (55.5)
219
-Migraine with aura (92)
144 - Germany Caucasian rs4680 No association. Mössner et al., 2006 [15]
-Migraine without aura (127)




Italy Caucasian rs4680 No association. Cevoli et al., 2006 [16]
-Migraine without aura without
drug abuse (101)
-Controls (over 40)
97 Migraine without aura (97) 94 - Korea Asian rs4680
Met allele associated with a
higher pain intensity of
headache (P = 0.001) and
nausea/vomiting occurring
(P = 0.026).
Park et al., 2007 [17]
263
Migraine without aura (55.9%) 274 -Patients (37 ± 16)
Spain Caucasian
rs2020917
No association. Corominas et al., 2009 [18]
rs933271
rs1544325










Migraine with aura (270)
272 - Germany Caucasian
rs933271






















Table 1 Reported association studies between COMT polymorphisms and migraine (pts: patients) (Continued)




USA, White race ~ 90% rs4680
Significant association with
migraine (P = 0.001) and
hormonally modulated migraine
(P = 0.03)




-1st cohort: Migraine without
aura (75)
- - Italy Caucasian rs4680
Significant association between
the Val/Val genotype and
response to triptans.
Cargnin et al., 2013 [21]-2nd cohort: Migraine without
aura (111)
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GTGCTCACCTCTCCTCC-3′ and R5′- CAGGTCTGAC
AACGGGTC-3′.
All Sanger sequencing analyses were carried out in order
to exclude pre-analytical and analytical errors on both
strands using Big Dye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems), run on an ABI 3130 Genetic
Analyzer (Applied Biosystems) and repeated on PCR prod-
ucts obtained from new nucleic acid extractions.
Statistics
Data are presented as mean and standard deviation
(SD). The allelic frequencies were estimated by gene
counting, and the genotypes were scored. The observed
numbers of COMT genotypes were compared with that
expected for a population in Hardy-Weinberg equilib-
rium. The significance of the differences of observed al-
leles, genotypes and haplotypes between groups as well
as analysis of multiple inheritance models (codominant,
dominant, recessive, overdominant, and log-additive) were
also tested using SNPStats (http://bioinfo.iconcologia.net/
snpstats/start.htm).
Association of nominal variables was assessed by chi
square test of Fisher-Freeman-Halton (FFH) test where
needed. For continuous variables, association with a factor
was assessed by General Linear Model (GLM) corrected
for sex and familiarity for migraine with Tukey’s HSD
(Honest Significant Difference) post hoc test. All calcula-
tions were made by SPPS 20 (IBM Corp, Armonk, NY),
except for power analysis, done by G*Power 3.1.3 free
software (Heinrich Heine Universitat, Dusseldorf, Ge).
The statistical power reached for GLM for fixed main ef-
fects was of 94.5% for an effect size f 0.2 and a type I error
probability of 5%.Table 2 Distributions of genotype and allele frequencies of C
patients and controls
N rs4680 genotypes (%)
AA (Met/Met) AG (Met/Val)
Controls 132 23 (17.4) 65 (49.2)
All patients with migraine 380 78 (20.5) 192 (50.5)
Migraine with Aura 65 15 (23.1) 30 (46.1)
Migraine w/out Aura 189 41 (21.7) 96 (50.8)
Chronic Migraine 126 22 (17.5) 66 (52.4)
N rs4818 genotypes (%)
CC (Leu/Leu) CG (Leu/Leu)
Controls 132 30 (22.7) 76 (57.6)
All patients with migraine 380 111 (29.3) 197 (51.8)
Migraine with Aura 65 21 (32.3) 30 (46.2)
Migraine w/out Aura 189 50 (26.5) 104 (55.0)
Chronic Migraine 126 40 (31,7) 63 (50.0)
Values are given as no. (%). HW: Hardy-Weinberg equilibrium.Study results
Our study population consists of 380 Caucasian individ-
uals affected by migraine (MwoA = 49,7%, MwA = 17,1%,
CM = 33,2%), and 132 healthy subjects. Table 2 reports
genotypes and allele frequencies of the rs4818 and rs4680
polymorphisms. No significant differences were found be-
tween these frequencies and those predicted by the Hardy-
Weinberg equilibrium. Haplotype analysis revealed no
linkage disequilibrium between the analyzed polymor-
phisms. We also tested differences of genotypes between
groups by analysis of multiple inheritance models but they
were not statistically significant (Table 3).
We found no association between rs4818 and rs4680
polymorphisms and migraine susceptibility (P = 0.336, and
P = 0.577, respectively), migraine type (MwoA, MwA, CM)
(P = 0.620, P = 0.858), gender (P = 0.081, P = 0.220), mean
age of onset (P = 0.821, P = 0.526), laterality of attacks (P =
0.917, P = 0.954), dopaminergic symptoms (P = 0.615, P =
0.089), unilateral cranial autonomic symptoms (P = 0.233,
P = 0.680), migraine prophylaxis (P = 0.489, P = 0.900), an-
algesics overuse (P = 0.647, P = 0.399), type of analgesic
overused (P = 0.800, P = 0368) or other clinical and
sociodemographic characteristics (data not shown). No
association was found between COMT rs4818 and rs4680
genotypes and pharmacological treatment response, par-
ticularly in the 218 patients treated with triptans (P = 0.558,
P = 0.956). Furthermore, no correlation was found between
rs4818 and rs4680 polymorphisms and pure menstrual or
menstrual related migraine (n = 85 pts) (P > 0.05).
Discussion
The study of COMTgene polymorphisms in migraine is in-
triguing since an impaired catecholaminergic neurotrans-
mission, namely a chronic dopaminergic and noradrenergicOMT polymorphism rs4680 and rs4818 observed in
rs4680 alleles (%) HW (P value)
GG (Val/Val) A G
44 (33.3) 111 (42.0) 153 (58.0) 0,90
110 (28.9) 348 (45.7) 412 (54.3) 0,73
20 (30.8) 60 (46.2) 70 (53.8) 0,56
52 (27.5) 178 (47.1) 200 (52.9) 0,79
38 (30.1) 110 (43.7) 142 (56.3) 0,47
rs4818 alleles (%) HW (P value)
GG (Leu/Leu) C G
26 (19.7) 136 (51.5) 128 (48.5) 0,08
72 (18.9) 419 (55.1) 341 (44.9) 0,35
14 (21.5 ) 72 (55.4) 58 (44.6) 0,59
35 (18.5) 204 (54.0) 174 (46.0) 0,14
23 (18.3) 143 (56.7) 109 (43.3) 0,84
Table 3 Differences of genotypes distributions between Migraine groups and multiple inheritance models using the WEB Tool SNPStats
(http://bioinfo.iconcologia.net/snpstats/start.htm)
Migraine with Aura Migraine w/out Aura Chronic Migraine
Model rs4680 genotypes OR (95% CI) P-value rs4680 genotypes OR (95% CI) P-value rs4680 genotypes OR (95% CI) P-value
Codominant G/G 1.00 0.65 G/G 1.00 0.44 G/G 1.00 0.87
A/G 1.02 (0.51-2.01) A/G 1.25 (0.75-2.08) A/G 1.16 (0.67-2.01)
A/A 1.43 (0.62-3.32) A/A 1.51 (0.79-2.89) A/A 1.11 (0.53-2.29)
Dominant G/G 1.00 0.72 G/G 1.00 0.26 G/G 1.00 0.61
A/G-A/A 1.12 (0.59-2.13) A/G-A/A 1.32 (0.81-2.13) A/G-A/A 1.14 (0.68-1.94)
Recessive G/G-A/G 1.00 0.35 G/G-A/G 1.00 0.34 G/G-A/G 1.00 0.97
A/A 1.42 (0.68-2.95) A/A 1.31 (0.74-2.32) A/A 1.01 (0.53-1.93)
Overdominant G/G-A/A 1.00 0.68 G/G-A/A 1.00 0.78 G/G-A/A 1.00 0.66
A/G 0.88 (0.49-1.60) A/G 1.06 (0.68-1.66) A/G 1.12 (0.68-1.82)
Log-additive --- 1.18 (0.77-1.79) 0.44 --- 1.23 (0.89-1.70) 0.2 --- 1.07 (0.75-1.52) 0.72
Model rs4818 genotypes OR (95% CI) P-value rs4818 genotypes OR (95% CI) P-value rs4818 genotypes OR (95% CI) P-value
Codominant C/C 1.00 0.27 C/C 1.00 0.75 C/C 1.00 0.24
C/G 0.56 (0.28-1.14) C/G 0.82 (0.48-1.41) C/G 0.61 (0.34-1.09)
G/G 0.77 (0.33-1.81) G/G 0.81 (0.41-1.59) G/G 0.66 (0.32-1.38)
Dominant C/C 1.00 0.15 C/C 1.00 0.45 C/C 1.00 0.095
C/G-G/G 0.62 (0.32-1.19) C/G-G/G 0.82 (0.49-1.38) C/G-G/G 0.63 (0.36-1.09)
Recessive C/C-C/G 1.00 0.76 C/C-C/G 1.00 0.79 C/C-C/G 1.00 0.79
G/G 1.12 (0.54-2.32) G/G 0.93 (0.53-1.63) G/G 0.92 (0.49-1.71)
Overdominant C/C-G/G 1.00 0.13 C/C-G/G 1.00 0.65 C/C-G/G 1.00 0.2
C/G 0.63 (0.35-1.15) C/G 0.90 (0.58-1.41) C/G 0.73 (0.44-1.19)
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first COMT study performed on a cohort of carefully clin-
ical characterized Caucasian migraineurs recruited in a
specifically dedicated migraine biobank [23] and focused
on the role of rs4818 variant, the polymorphism most
strongly affecting COMT activity. In our association ana-
lysis the control group was chosen balance the average
size of the three pathological groups considered. There-
fore, power analysis showed that such a setup sufficed the
requirement of at least 90% sensitivity respect to a pretty
small effect size (almost comparable to an Odds Ratio of
2.066). In our opinion the power we reached ensured that
the negative findings we reported were due to a lack of
significant association, rather than to a misrecognized
negligible effect.
The main finding of the present study is that COMT
rs4818 polymorphism does not influence the susceptibil-
ity or clinical phenotype of MwoA, MwA or CM, even
when considering migraine patients subsets, such as those
characterized before or during the attack by symptoms
due to pre- or post-synaptic dopamine receptor activation,
such as yawning, vomiting and hypotension (dopaminergic
migraineurs) [3] or those with pure menstrual or menstru-
ally related migraine (hormonally modulated migraine,
HMM [20]). Moreover, our replication study supports pre-
vious results excluding any correlation between COMT
rs4680 polymorphism and migraine in Caucasians patients
[14-16,18,19], in contrast with a putative correlation found
only in Korean and Turkish population [13,17]. Such dis-
crepancies may be related either to smaller sample size or
to differences in variant frequency related to race/ethnicity
of different population studies.
Our results do not confirm the hypothesis that COMT
rs4680 genotype influences the clinical response to trip-
tans as previously suggested [21], albeit our study was
performed on a comparable patients sample (218 vs 198
pts). Possible explanations include the fact that our
study was not selectively focused on triptans clinical re-
sponse and considered different criteria to assess triptan
responsivity. Finally we did not find significant associ-
ation between the rs4680 variant and HMM as previ-
ously reported by Sullivan et al. [20] probably due to the
unequal proportion of women with this subtype of mi-
graine in the present study.
Our study, reasonably, cuts out a direct involvement
of COMT gene polymorphisms in migraine even when
considering the rs4818 polymorphism. This is not necessar-
ily in contrast with the catecholaminergic derangement
widely described in migraine [1]. We suggest that probably
other catecholamine catabolic or biosynthetic enzymes,
such as monoamine-oxidase, dopamine beta-hydroxylase,
tyrosine-hydroxylase or tyrosine-decarboxylase are involved
in the dopaminergic and noradrenergic impairment charac-
terizing migraine sufferers [1-3].Catecholamines originate from tyrosine metabolism
through a hydroxylase-related pathway. In migraineurs,
a reduction in mitochondrial energy would favour a
metabolic shift directing tyrosine metabolism toward
decarboxylation pathway instead of the hydroxylation
one, leading to reduced catecholamines production and
high trace amine levels in the pain matrix, and, ultim-
ately, to the trigemino-vascular system activation, trig-
gering the attack [1].
We acknowledge that potential recall bias and the re-
cruitment in a tertiary-referral center are limitations of
our study. Strengths include the use of data based on a
specifically dedicated migraine biobank and a careful
clinical and demographic characterization of all patients
studied using with face-to-face interviews.
Conclusions
In conclusion, COMT genotype does not influence mi-
graine susceptibility or phenotype, even when considering
peculiar clinical subtypes (dopaminergic migraine, HMM).
This finding coupled with the well established catechol-
aminergic imbalance characterizing migraine biotypes
prompts to a thorough investigation of other enzymes
involved in catecholamines synthesis and catabolism.
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